Although the functions of long noncoding RNA (lncRNA) called FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) have been well studied in multiple human cancer types, its expression status and detailed roles in cervical cancer remain unknown and merit investigation. This study was aimed at assessing FOXD2-AS1 expression in cervical cancer and at determining its effects on the aggressive behavior of cervical cancer in vitro and in vivo. Expression of FOXD2-AS1 in cervical cancer tissues and cell lines was determined via reverse-transcription quantitative PCR. The effects of FOXD2-AS1 on cervical cancer cells were examined by a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-Htetrazolium bromide (MTT) assay, flow-cytometric analysis, migration and invasion assays, and an in vivo tumorigenicity assay. FOXD2-AS1 was found to be significantly upregulated in cervical cancer tissues and cell lines. High FOXD2-AS1 expression was notably linked with the Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis, and depth of cervical invasion in patients with cervical cancer. Kaplan-Meier survival analysis revealed significantly shorter overall survival of patients when the tumor expression of FOXD2-AS1 was higher in comparison with those in patients with lower FOXD2-AS1 expression. In vitro functional assays revealed that downregulation of FOXD2-AS1 led to suppression of proliferation, migration, and invasiveness as well as to the induction of apoptosis of cervical cancer cells. In addition, FOXD2-AS1 silencing hindered tumor growth in vivo. Mechanism investigation revealed that FOXD2-AS1 functioned as a molecular sponge of microRNA-760 (miR-760). Furthermore, hepatoma-derived growth factor (HDGF) was validated as a direct target gene of miR-760 in cervical cancer cells. Moreover, an miR-760 knockdown reversed the effects of FOXD2-AS1 silencing on cervical cancer cells. FOXD2-AS1 possesses significant oncogenic activity in cervical cancer progression; this activity is mediated by sponging
INTRODUCTION
Cervical cancer is the second most prevalent cancer among women and the fourth leading cause of gynecological-cancerassociated deaths globally (Torre et al., 2015) . Approximately 530,000 new cases are expected every year, and 275,000 deaths are caused by cervical cancer worldwide annually (Arbyn et al., 2011) . Over 75% of these new cases and deaths occur in developing countries, including China (Barra et al., 2017) . Multiple factors, including early sexual intercourse, an increased number of sexual partners, and persistent human papillomavirus infection, have been implicated in the pathogenesis of cervical cancer (Bosch and de Sanjose, 2003; Yu et al., 2013) ; however, the detailed mechanisms behind the progression of cervical cancer remain largely unclear and need further elucidation. Despite considerable progress in the diagnostic and therapeutic modalities in recent years, the clinical outcomes of patients with cervical cancer unfortunately remain unsatisfactory (Ghebre et al., 2017) . The 5-year survival rate of patients with cervical cancer diagnosed at advanced stages is less than 40%, which may be attributable to metastasis and tumor recurrence (Smith et al., 2013; Kogo et al., 2015) . Therefore, elucidation of the mechanisms underlying cervical carcinogenesis and cancer progression is crucial and may facilitate identification of novel therapeutic targets to improve the prognosis of patients with cervical cancer.
Long noncoding RNAs (lncRNAs) are a group of RNA molecules with a length of >200 nucleotides that do not encode proteins (Batista and Chang, 2013) . LncRNAs are widely expressed in nearly all organs and are implicated in a variety of biological and pathological processes (Ponting et al., 2009) . They can function as molecular sponges, scaffolds, and guides for interactions with proteins, mRNAs, or microRNAs (miRNAs), thereby regulating the expression of target genes (Anastasiadou et al., 2018) . Accumulated evidence indicates that many lncRNAs are aberrantly expressed in cervical cancer (Chen et al., 2019; Zhang X. et al., 2019) . Alterations in the expression of lncRNAs are involved in cervical carcinogenesis and cancer progression by playing tumorsuppressive or oncogenic roles (Aalijahan and Ghorbian, 2019) . Hence, an in-depth understanding of novel lncRNAs associated with the aggressive behaviors of cervical cancer may contribute to the development of attractive targets for anticancer therapy.
MiRNAs are a subset of endogenous, single-strand, noncoding small RNAs ranging in size from 17 to 21 nucleotides (Kloosterman and Plasterk, 2006) . MiRNAs re gulate gen e expre ssion by interac ting with the complementary sequences in the 3′ untranslated region (3′-UTR) of a target mRNA and by triggering translation suppression and/or mRNA degradation (Bartel, 2009) . One mRNA can be directly targeted by numerous miRNAs, and one miRNA is likely to target numerous mRNAs (Zang et al., 2016) . MiRNAs are aberrantly expressed in nearly all human cancer types, including cervical cancer (Mandujano-Tinoco et al., 2018; Srivastava et al., 2017; Sharma and Baruah, 2018) . MiRNAs may function either as oncomiRs or tumor suppressor miRNAs depending on their target genes (Xia et al., 2016) . In particular, a wide range of miRNAs are dysregulated in cervical cancer and are involved in the modulation of various pathological and physiological phenomena, including cell proliferation, the cell cycle, apoptosis, metastasis, angiogenesis, and chemoresistance (Feng et al., 2017; Li et al., 2017; Laengsri et al., 2018) . Therefore, miRNAs may be promising therapeutic targets for the management of cervical cancer.
FOXD2-AS1 is dysregulated in multiple types of human cancer, and its dysregulation is involved in the modulation of various tumor-associated biological processes (Rong et al., 2017; Bao et al., 2018; Chang et al., 2018; Su et al., 2018; Zhang et al., 2018; Zhao et al., 2018; Zhu et al., 2018; Jiang et al., 2019; Liu et al., 2019; Ni et al., 2019; Ren et al., 2019; Xu et al., 2019) . To the best of our knowledge, however, the expression status and detailed roles of FOXD2-AS1 in cervical cancer are still unknown. Therefore, the objectives of this study were to evaluate FOXD2-AS1 expression in cervical cancer, investigate the effects of FOXD2-AS1 on cervical cancer cells, and elucidate the potential mechanism underlying these effects. Our study identified a novel pathway, FOXD2-AS1-miR-760-HDGF, involved in cervical cancer progression.
MATERIALS AND METHODS

Clinical Tissue Samples
In total, 63 pairs of cervical cancer tissue samples and adjacent noncancerous tissues were collected from patients with cervical cancer who underwent surgical resection in The First Affiliated Hospital of Zhejiang Chinese Medical University. None of the patients underwent chemotherapy, radiotherapy, or other anticancer therapy prior to the surgical procedure. Tissue specimens were quickly snap-frozen in liquid nitrogen after the surgical resection and then transferred to a −80°C freezer for storage until RNA extraction. The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Zhejiang Chinese Medical University. Written informed consent was provided by all participants before the collection of tissue samples.
Cell Lines and Culture Conditions
A normal human cervix epithelial cell line (Ect1/E6E7) was acquired from the American Type Culture Collection (Manassas, VA, USA). Four human cervical cancer cell lines (HeLa, C-33A, SiHa, and CaSki) were ordered from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) of heat-inactivated fetal bovine serum (FBS) and 1% (v/v) of a penicillin/streptomycin solution (all from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to culture all the above cell lines. All cells were grown at 37°C in a humidified incubator supplied with 5% CO 2 .
A Gene Knockdown and Overexpression
The mimic, negative control mimic (miR-NC), inhibitor, and NC inhibitor for miR-760 were obtained from GenePharma Co., Ltd. (Shanghai, China). For a FOXD2-AS1 knockdown, small interfering RNA (siRNA) was used (si-FOXD2-AS1); this oligo and negative control siRNA (NC siRNA) were chemically synthesized by RiboBio Co., Ltd. (Guangzhou, China). For HDGF upregulation, HDGF overexpression plasmid pcDNA3.1-HDGF (pc-HDGF) and the empty pcDNA3.1 vector were purchased from the Chinese Academy of Sciences (Changchun, China) . Approximately 12 h before transfection, cells were seeded in 6-well plates. The above-mentioned oligos were transfected into the cells by means of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's protocol.
RNA Extraction and Reverse-Transcription Quantitative PCR (RT-qPCR)
The TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was utilized to isolate total RNA from tissue specimens or cells in line with the manufacturer's protocol. The concentration of total RNA was measured on a NanoDrop Spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). Total RNA was converted into cDNA using the miScript Reverse Transcription Kit (Qiagen GmbH, Hilden, Germany). The synthesized cDNA was used for the quantification of miR-760 expression with the miScript SYBR Green PCR Kit (Qiagen GmbH). Internal control for miR-760 was U6 small nuclear RNA. To analyze FOXD2-AS1 and HDGF mRNA expression, reverse transcription was conducted with the PrimeScript RT Reagent Kit (Takara Biotechnology Co., Ltd., Dalian, China). Next, qPCR was carried out with SYBR Premix Ex Taq ™ (Takara Biotechnology Co., Ltd.). GAPDH served as an internal reference for FOXD2-AS1 and HDGF. Relative gene expression was calculated by the 2 −DDCt method (Livak and Schmittgen, 2001) .
A 3-(4,5-Dimethyl-2-Thiazolyl)-2,5-Diphenyl-2-H-Tetrazolium Bromide (MTT) Assay
Transfected cells were collected after 24 h of incubation and seeded separately in 96-well plates at a density of 3,000 cells/well. The cells were then incubated at 37°C and 5% CO 2 . The MTT assay was performed at four time points as follows: 0, 24, 48, and 72 h after cell seeding. In particular, 20 µl of the MTT reagent (5 mg/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was added into each well, and the cells were incubated at 37°C and 5% CO 2 for another 4 h. After that, the culture medium was removed followed by the addition of 200 µl of dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) to dissolve the violet formazan crystals. Finally, a microplate reader (BioRad Laboratories, Hercules, CA, USA) was employed to measure optical density at 490 nm wavelength.
Flow-Cytometric Analysis
Transfected cells were collected after 48 h of incubation. 
Migration and Invasion Assays
After 48 h of transfection, the invasive ability of cervical cancer cells was examined by means of 24-well Transwell chambers (24-well insert; pore size: 8 µm; Corning Inc., Corning, NY, USA) precoated with Matrigel (BD Biosciences). Briefly, transfected cells were harvested and resuspended in the FBS-free culture medium. In total, 5 × 10 4 cells were seeded in the upper compartment of each insert, while the lower compartment was filled with 500 µl of DMEM containing 20% of FBS. After 24 h incubation, noninvading cells were gently removed by swabbing the top layer of Matrigel with a cotton swab. The invading cells adhering to the undersurface of the insert were fixed with 100% methanol followed by staining with 0.5% crystal violet and washing with PBS. The invasive ability was assessed by counting the invading cells in five randomly chosen visual fields per insert under a light microscope (200× magnification; Olympus Corporation, Tokyo, Japan). The migration assay was carried out according to the experimental procedures similar to those of the invasion assay, except that the chambers were not coated with Matrigel.
An In Vivo Tumorigenicity Assay
Four-week-old female BALB/c nude mice were ordered from Shanghai SLAC Laboratory Animal Co., Ltd., (Shanghai, China). HeLa cells transfected with si-FOXD2-AS1 or si-NC were subcutaneously injected into the flank of nude mice. The width and length of tumor xenografts were measured every 2 days. Four weeks after injection, all the nude mice were euthanized, after which the tumor xenografts were excised and weighed. The volumes of tumor xenografts were calculated using the following formula: (length × width 
Target Prediction and a Luciferase
Reporter Assay starBase 3.0 (http://starbase.sysu.edu.cn/) was utilized to search for the miRNAs that could be sponged by FOXD2-AS1. Three bioinformatics tools, TargetScan7.1 (http://www.targetscan.org/), miRDB (http://mirdb.org/), and starBase 3.0, were employed to predict the potential targets of miR-760.
For a luciferase reporter assay, the 3′-UTR fragments of HDGF containing the wild-type (WT) miR-760-binding sequences and a corresponding mutant (MUT) 3′-UTR fragment were designed and chemically synthesized by Shanghai GenePharma and subcloned into pMIR-REPOR (Promega Corp., Madison, WI, USA). The generated luciferase plasmids were designated as HDGF-WT and HDGF-MUT, respectively. The luciferase plasmids, FOXD2-AS1-WT and FOXD2-AS1-MUT, were chemically synthesized in the same way. Cotransfection with the luciferase plasmid and either the miR-760 mimic or miR-NC into cells was performed using the Lipofectamine 2000 reagent following the manufacturer's instructions. Luciferase activities were determined at 48 h after cell transfection by means of a Dual-Luciferase Reporter Assay System (Promega Corp.). The relative luciferase activity was normalized to Renilla luciferase activity.
RNA Immunoprecipitation (RIP) Assay
The Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Bedford, MA, USA) was used for the RIP assay. Briefly, cells were harvested and lysed with RIP lysis buffer. Next, incubation of 100 ml of the cell extract and RIP buffer containing magnetic beads conjugated to an anti-Argonaute 2 (AGO2) antibody (Millipore) or IgG antibody (Millipore) was performed. To remove the protein, proteinase K was applied to treat the samples, after which the immunoprecipitated RNA was extracted and subjected to RT-qPCR for the measurement of FOXD2-AS1 and miR-760 expression.
Protein Extraction and Western Blot Analysis
Total protein was extracted from transfected cells after 72 h of incubation using ice-cold radioimmunoprecipitation assay buffer (Invitrogen; Thermo Fisher Scientific, Inc.). The concentration of total protein was measured with the BCA Protein Assay Kit (Shanghai Qcbio Science and Technologies Co., Ltd., Shanghai, China). Equal amounts of protein samples were loaded onto each lane for SDS-PAGE, followed by transfer onto polyvinylidene difluoride membranes (Beyotime Institute of Biotechnology, Haimen, China). After blockage at room temperature with 5% dried skimmed milk diluted in Tris-buffered saline containing 0.1% of Tween 20 for 1 h, the membranes were incubated with a rabbit anti-human HDGF monoclonal antibody (1:1000 dilution; cat. # ab128921; Abcam, Cambridge, UK) and a rabbit antihuman GAPDH monoclonal antibody (1:1000 dilution; ab181603; Abcam) overnight at 4°C and next probed with a goat anti-rabbit IgG antibody (horseradish peroxidase conjugate; 1:5000 dilution; ab205718; Abcam) (secondary antibody) at room temperature for 1 h. The protein signals were visualized with the Enhanced Chemiluminescence Kit (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.
Statistical Analysis
Data were presented as the mean ± standard deviation. The c 2 test was performed to investigate the correlation between FOXD2-AS1 expression and clinical parameters among the patients with cervical cancer. Differences between two groups were analyzed by Student's t test. One-way analysis of variance, followed by the Student-Newman-Keuls post hoc test, was conducted to evaluate the differences between more than two groups. Expression of FOXD2-AS1, miR-760, and HDGF tested from cervical cancer tissues and adjacent noncancerous tissue samples was analyzed with paired t-tests. The expression correlations between miR-760 and HDGF mRNA levels or between FOXD2-AS1 and miR-760, were assessed by Spearman's correlation analysis. Kaplan-Meier survival analysis was carried out to assess patients' survival. Data with P < 0.05 were assumed to indicate a statistically significant difference.
RESULTS
Upregulation of FOXD2-AS1 Is Linked to Poor Survival Among Patients With Cervical Cancer
To reveal the expression pattern of FOXD2-AS1 in cervical cancer, we detected its expression in 63 pairs of cervical cancer tissue samples and adjacent noncancerous tissue samples by RTqPCR. The results showed that FOXD2-AS1 was significantly upregulated in cervical cancer tissues when compared with noncancerous tissues ( Figure 1A , P < 0.05). To evaluate the clinical significance of FOXD2-AS1 in cervical cancer, we subdivided all patients with cervical cancer into low-and high-FOXD2-AS1 groups based on a median level of FOXD2-AS1 expression and then investigated the association between FOXD2-AS1 and the clinical parameters of patients with cervical cancer. Statistical analysis revealed that high FOXD2-AS1 levels strongly correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.045), lymph node metastasis (P = 0.023), and depth of cervical invasion (P = 0.036) among the patients with cervical cancer (Table 1) . Notably, Kaplan-Meier survival analysis revealed significantly shorter overall survival when the expression of FOXD2-AS1 was higher than when this expression was lower ( Figure 1B , P = 0.019). To further validate the correlation of FOXD2-AS1 with cervical cancer, FOXD2-AS1 expression was measured in four cervical cancer cell lines (HeLa, C-33A, SiHa, and CaSki) and a normal human cervix epithelial cell line (Ect1/E6E7) by the same method. The expression level of FOXD2-AS1 was considerably higher in all four cervical cancer cell lines than in Ect1/E6E7 cells ( Figure 1C , P < 0.05). These findings suggested that FOXD2-AS1 may be closely related to the aggressiveness of cervical cancer.
Inhibition of FOXD2-AS1 Expression Suppresses Cervical Cancer Cell Proliferation, Migration, and Invasion and Promotes Apoptosis
To reveal the exact roles of FOXD2-AS1 in the progression of cervical cancer, HeLa and SiHa cell lines, which showed relatively high FOXD2-AS1 expression among the four cervical cancer cell lines, were selected for functional analysis and were transfected with si-FOXD2-AS1. In the two cell lines, the successful downregulation of FOXD2-AS1 was confirmed via RT-qPCR ( Figure 2A , P < 0.05). The effect of the FOXD2-AS1 knockdown on the proliferation of cervical cancer cells was tested by the MTT assay. The data revealed that the knockdown of FOXD2-AS1 decreased the proliferation of HeLa and SiHa cells ( Figure  2B , P < 0.05). In addition, during quantitation of apoptotic cells by flow cytometry, si-FOXD2-AS1-transfected HeLa and SiHa cells were found to have a higher apoptosis rate compared with the cells transfected with si-NC ( Figure 2C , P < 0.05). Furthermore, the cell motility was determined by migration and invasion assays, and the results showed that the migration ( Figure 2D , P < 0.05) and invasiveness ( Figure 2E , P < 0.05) of HeLa and SiHa cells obviously decreased after si-FOXD2-AS1 transfection. These observations revealed oncogenic roles of FOXD2-AS1 in the proliferation, apoptosis, migration, and invasiveness of cervical cancer cells.
FOXD2-AS1 Sponges miR-760 in Cervical Cancer
The mechanisms behind the oncogenic activity of FOXD2-AS1 in cervical cancer were investigated next. Competitive endogenous RNA is a well-known regulatory role of lncRNA. LncRNAs may sponge certain miRNAs to inhibit the expression of these miRNAs. A bioinformatics tool, namely starBase 3.0, was used to search for the miRNAs that could interact with FOXD2-AS1 based on the complementarity of bases. MiR-760 ( Figure 3A) was found to contain a sequence complementary to FOXD2-AS1, and this miRNA was selected for verification because miR-760 exerts tumor-suppressive actions in a variety of human cancers (Hu et al., 2016; Liao et al., 2016; Cao et al., 2018; Yan et al., 2018). The luciferase reporter assay was conducted to test this prediction, and the results showed that upregulation of miR-760 ( Figure 3B , P < 0.05) caused by miR-760 mimic transfection resulted in obvious suppression of the luciferase activity of FOXD2-AS1-WT (P < 0.05); however, the luciferase activity of FOXD2-AS1-MUT stayed unaltered in HeLa and SiHa cells after miR-760 overexpression ( Figure 3C ). The RIP assay indicated that both FOXD2-AS1 and miR-760 were immunoprecipitated by the anti-AGO2 antibody in HeLa and SiHa cell lysates, suggesting that miR-760 is a FOXD2-AS1 target ( Figure 3D , P < 0.05). Next, the expression of miR-760 in FOXD2-AS1-deficient HeLa and SiHa cells was determined by RT-qPCR. The downregulation of FOXD2-AS1 in HeLa and SiHa cells caused significant upregulation of miR-760 expression ( Figure 3E , P < 0.05). Furthermore, miR-760 expression was notably lower in cervical cancer tissue samples than in noncancerous tissue samples ( Figure 3F , P < 0.05). Notably, cervical cancer tissue samples manifested an inverse correlation between the expression levels of FOXD2-AS1 and miR-760 ( Figure 3G , R 2 = 0.4092; P < 0.0001). To sum up, FOXD2-AS1 sponged miR-760 in cervical cancer cells.
MiR-760 Functions as a TumorSuppressive miRNA in Cervical Cancer Cells
Next, we examined the involvement of miR-760 in the malignant characteristics of cervical cancer. Because miR-760 expression was low in cervical cancer, gain-of-function experiments were performed on HeLa and SiHa cells after miR-760 mimic or miR-NC transfection. The MTT assay and flow cytometry revealed that the ectopic miR-760 expression restricted the proliferation ( Figure 4A , P < 0.05) and induced apoptosis ( Figure 4B , P < 0.05) of HeLa and SiHa cells. After that, the migration and invasiveness of HeLa and SiHa cells were tested in migration and invasion assays after overexpression of miR-760. When HeLa and SiHa cells were transfected with the miR-760 mimic, their migratory ( Figure 4C , P < 0.05) and invasive ( Figure 4D , P < 0.05) abilities significantly decreased as compared with those of miR-NC-transfected cells. Collectively, these results revealed the tumor-suppressive functions of miR-760 in cervical cancer cells.
HDGF mRNA Is the Direct Target of miR-760 in Cervical Cancer
To elucidate the mechanisms underlying the roles of miR-760 in cervical cancer, bioinformatics analysis was carried out and predicted that the 3′-UTR of HDGF mRNA harbors a potential miR-760-binding site ( Figure 5A ). After that, the luciferase reporter assay was applied to determine whether miR-760 can directly target the 3′-UTR of HDGF mRNA in cervical cancer cells. As presented in Figure 5B , upregulation of miR-760 significantly decreased the luciferase activities of the luciferase plasmid harboring the wild-type 3′-UTR of HDGF (P < 0.05) in HeLa and SiHa cells; however, this effect was abrogated when the binding site in the 3′-UTR of HDGF was mutated.
The relation between miR-760 and HDGF was further examined by quantification of the HDGF expression in cervical cancer tissues. The mRNA level of HDGF was found to be much higher in cervical cancer tissue samples than in noncancerous tissue samples ( Figure 5C , P < 0.05). HDGF expression was then compared with miR-760 expression in the same cervical cancer tissue samples. A significant inverse correlation was uncovered by Spearman's correlation analysis ( Figure 5D ; R 2 = 0.3554; P < 0.0001). Furthermore, RT-qPCR and western blotting revealed that the expression levels of HDGF mRNA ( Figure 5E , P < 0.05) and protein ( Figure 5F , P < 0.05) were noticeably lower in HeLa and SiHa cells after miR-760 overexpression. Collectively, these results strongly indicated that HDGF mRNA is a direct target of miR-760 in cervical cancer cells.
HDGF Restoration Counteracts the Effects of miR-760 Overexpression on the Malignant Characteristics of Cervical Cancer Cells
MiR-760 was found to act as a tumor-suppressive miRNA in cervical cancer, and HDGF mRNA was validated as a direct target of miR-760; hence, the tumor-suppressive actions of miR-760 in cervical cancer cells were next postulated to be mediated by HDGF downregulation. To test this hypothesis, HDGF overexpression plasmid pcDNA3.1-HDGF (pc-HDGF) or the empty pcDNA3.1 plasmid was cotransfected with the miR-760 mimic into HeLa and SiHa cells. Cotransfection with pc-HDGF efficiently reversed HDGF downregulation by the miR-760 mimic in HeLa and SiHa cells, as indicated by western blotting ( Figure 6A , P < 0.05). After that, we discovered that restoration of HDGF expression obviously attenuated the influence of miR-760 overexpression on the proliferation ( Figure 6B , P < 0.05), apoptosis ( Figure 6C , P < 0.05), migration ( Figure 6D , P < 0.05), and invasiveness ( Figure 6E , P < 0.05) of HeLa and SiHa cells. In summary, these results supported the hypothesis that miR-760 overexpression restrained the malignant phenotype of cervical cancer cells, at least partly, by decreasing HDGF expression.
MiR-760 Downregulation Reverses the Effects of FOXD2-AS1 Silencing on Cervical Cancer Cells
To further test the involvement of miR-760 in the role induced by FOXD2-AS1 on the oncogenicity of cervical cancer cells, miR-760 inhibitor or NC inhibitor was introduced into FOXD2-AS1-deficient HeLa and SiHa cells, followed by investigation of the ability of these cells to proliferate, undergo apoptosis, migrate, and invade. The cotransfection of miR-760 inhibitor, which efficiently silenced miR-760 expression ( Figure 7A , P < 0.05), weakened the FOXD2-AS1 knockdown-mediated upregulation of miR-760 ( Figure 7B , P < 0.05) and downregulation of HDGF protein ( Figure 7C 7D, P < 0.05), apoptosis ( Figure 7E , P < 0.05), migration ( Figure  7F , P < 0.05), and invasion ( Figure 7G , P < 0.05) were notably attenuated in HeLa and SiHa cells by miR-760 inhibitor cotransfection. These results indicated that FOXD2-AS1 silencing exerted an inhibitory action on cervical cancer malignancy by targeting the miR-760-HDGF axis.
Depletion of FOXD2-AS1 Decreases Cervical Cancer Tumor Growth In Vivo
To characterize the influence of FOXD2-AS1 on tumor growth in vivo, an in vivo tumorigenicity assay was performed via injection of si-FOXD2-AS1 or si-NC-transfected HeLa cells into the flank of nude mice. Si-FOXD2-AS1 HeLa cell-injected nude mice showed slower tumor growth (Figures 8A, B ; P < 0.05) and smaller tumor weight ( Figure 8C , P < 0.05) than the si-NC HeLa cell-injected ones. In addition, the tumor xenografts of the si-FOXD2-AS1 group featured downregulation of FOXD2-AS1 ( Figure 8D , P < 0.05), higher miR-760 expression ( Figure 8E , P < 0.05), and lower HDGF mRNA ( Figure 8F , P < 0.05) and protein expression ( Figure 8G , P < 0.05) relative to those in the si-NC group. Consistently with the in vitro findings, downregulation of FOXD2-AS1 decreased the expression of HDGF via reduced sponging of miR-760, thereby inhibiting tumor growth in vivo.
DISCUSSION
LncRNAs are a large subgroup of noncoding RNAs that have emerged as regulators of crucial processes in various human cancers including cervical cancer (Aalijahan and Ghorbian, 2019) . In recent decades, multiple lncRNAs have been reported to be aberrantly expressed in cervical cancer, and their aberrant expression plays important roles in the aggressive phenotype of cervical cancer Dong et al., 2017; Wang et al., 2017) . Hence, exploration of the detailed involvement of lncRNAs in cervical cancer and their mechanisms of action is necessary to discover promising targets for the diagnosis and treatment of patients with this cancer. In this study, we for the first time measured FOXD2-AS1 expression in cervical cancer and determined its clinical value in patients with cervical cancer. Notably, the biological roles and regulatory mechanism of action of FOXD2-AS1 in cervical cancer were investigated in detail. FOXD2-AS1 is overexpressed in bladder cancer, and upregulation of FOXD2-AS1 shows a significant correlation with tumor stage and tumor recurrence (Su et al., 2018) . The overall survival and progression-free survival of bladder cancer patients with high FOXD2-AS1 expression is shorter than that of bladder cancer patients with low FOXD2-AS1 expression (Su et al., 2018) . Overexpressed FOXD2-AS1 is observed in multiple other types of human cancer, including hepatocellular carcinoma (Chang et al., 2018; Zhao et al., 2018; Xu et al., 2019) , glioma (Ni et al., 2019) , thyroid cancer Jiang et al., 2019; Liu et al., 2019) , cutaneous melanoma (Ren et al., 2019) , colorectal cancer (Zhu et al., 2018) , esophageal squamous cell carcinoma (Bao et al., 2018) , and non-small cell lung cancer (Rong et al., 2017) . Nevertheless, FOXD2-AS1 expression status in cervical cancer has been unknown and warrants investigation. In this study, we found that FOXD2-AS1 expression is high in both cervical cancer tissues and cell lines. Elevated FOXD2-AS1 HDGF levels were linked with the FIGO stage, lymph node metastasis, and depth of cervical invasion among patients with cervical cancer. Patients with cervical cancer harboring high FOXD2-AS1 expression showed worse overall survival than those with low FOXD2-AS1 expression. These findings suggest that FOXD2-AS1 is a potential biomarker for the diagnosis and prognosis of cervical cancer. A knockdown of FOXD2-AS1 inhibits papillary thyroid cancer cell proliferation, migration, invasion, the cancer stem cell-like phenotype, and anoikis resistance in vitro; promotes apoptosis; and hinders tumorigenesis in vivo Jiang et al., 2019; Liu et al., 2019) . In hepatocellular carcinoma, silencing of FOXD2-AS1 expression suppresses cell proliferation, colony formation, metastasis, and epithelial-mesenchymal transition; induces cell cycle arrest at the G0-G1 transition; and decreases tumor growth and metastasis in vivo (Chang et al., 2018; Zhao et al., 2018; Xu et al., 2019) . FOXD2-AS1 also exerts oncogenic actions on carcinogenesis including progression of bladder cancer (Su et al., 2018) , glioma (Ni et al., 2019) , cutaneous melanoma (Ren et al., 2019) , colorectal cancer (Zhu et al., 2018), esophageal squamous cell carcinoma (Bao et al., 2018) , and non-small cell lung cancer (Rong et al., 2017) . Nevertheless, no studies have focused on specific functional roles of FOXD2-AS1 in the malignant characteristics of cervical cancer. Herein, we demonstrated that FOXD2-AS1 knockdown attenuates cervical cancer cell proliferation, migration, and invasion in vitro; increased apoptosis; and hindered tumor growth in vivo. These observations suggest that FOXD2-AS1 may be considered an effective target for cervical cancer therapies in the future. Exploration of the molecular mechanisms underlying the oncogenic activity of FOXD2-AS1 is essential for the identification of novel therapeutic methods for patients with cervical cancer. Our investigation of the mechanism revealed that FOXD2-AS1 may serve as a competitive endogenous RNA for miR-760. This miRNA is overexpressed in ovarian cancer (Liao et al., 2016) and functions as an oncogenic miRNA during cancer progression. On the contrary, miR-760 is underexpressed in hepatocellular carcinoma, non-small cell lung cancer (Yan et al., 2018) , colorectal cancer (Cao et al., 2018) , and breast cancer (Hu et al., 2016) . Functionally, miR-760 is reported to play a tumor-suppressive part in the aggressiveness of these human cancer types. The expression and participation of miR-760 in cervical cancer have been unclear. Our results revealed that miR-760 expression is low in cervical cancer. By contrast, miR-760 overexpression inhibited the malignancy of cervical cancer by suppressing cell proliferation, migration, and invasion and by increasing apoptosis. Therefore, our study for the first time revealed the crucial functions of the FOXD2-AS1-miR-760 pathway in cervical cancer.
After that, we explored the mechanisms behind the activities of miR-760 in cervical cancer. Our results identified HDGF as a direct target gene of miR-760 in cervical cancer, and downregulation of HDGF turned out to be essential for the biological functions of miR-760 in cervical cancer. HDGF is overexpressed in cervical cancer tissues in comparison with nontumor tissues. Upregulation of HDGF is closely related to lymph-vascular space invasion, lymph node metastasis, recurrence, and advanced grade among patients with cervical cancer (Tsai et al., 2014) . HDGF participates in the progression of cervical cancer by promoting cell proliferation, migration, and invasion (Song et al., 2017) . The results of the present study revealed that HDGF is directly regulated by the FOXD2-AS1-miR-760 pathway in cervical cancer and is involved in multiple cancer-related pathological processes.
The study had two limitations. First, Northern Blot assay was not applied to detect miR-760 expression in cervical cancer. Second, the impact of FOXD2-AS1 on the occurrence of cervical cancer was not explored in detail. We will resolve the limitations in the near further.
In summary, the present study shows that FOXD2-AS1 expression is high in cervical cancer, and this overexpression is associated with poor prognosis. Downregulation of FOXD2-AS1 inhibits the malignant characteristics of cervical cancer cells by decreasing competitive sponging of miR-760, thereby decreasing HDGF expression. The FOXD2-AS1-miR-760-HDGF pathway represents an effective target for the treatment of patients with cervical cancer.
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